Nicolas Penel
#161,859
Most Influential Person Now
Researcher
Nicolas Penel's AcademicInfluence.com Rankings
Nicolas Penelcomputer-science Degrees
Computer Science
#9381
World Rank
#9854
Historical Rank
Computational Linguistics
#2255
World Rank
#2278
Historical Rank
Machine Learning
#4088
World Rank
#4137
Historical Rank
Artificial Intelligence
#4428
World Rank
#4489
Historical Rank
Nicolas Penelmathematics Degrees
Mathematics
#7375
World Rank
#10041
Historical Rank
Measure Theory
#2105
World Rank
#2547
Historical Rank
Download Badge
Computer Science Mathematics
Nicolas Penel's Degrees
- PhD Computer Science Université Paris Cité
- Masters Computer Science Université Paris Cité
- Bachelors Mathematics Université Paris Cité
Similar Degrees You Can Earn
Why Is Nicolas Penel Influential?
(Suggest an Edit or Addition)Nicolas Penel's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. (2020) (1193)
- Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. (2008) (540)
- Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. (2012) (480)
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial (2018) (264)
- An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) (2017) (250)
- Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. (2013) (199)
- Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. (2011) (199)
- The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. (2020) (194)
- Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). (2012) (184)
- Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. (2016) (171)
- Advanced chondrosarcomas: role of chemotherapy and survival. (2012) (171)
- Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). (2012) (168)
- Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. (2019) (158)
- Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. (2019) (153)
- Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. (2016) (148)
- Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. (2009) (147)
- Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. (2019) (141)
- Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group (2017) (141)
- Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. (2018) (141)
- A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04) (2019) (139)
- Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. (2020) (134)
- Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. (2015) (130)
- Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas (2012) (119)
- Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? (2012) (119)
- Improved survival using specialized multidisciplinary board in sarcoma patients (2017) (119)
- Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study. (2019) (119)
- Multivariate analysis of risk factors for wound infection in head and neck squamous cell carcinoma surgery with opening of mucosa. Study of 260 surgical procedures. (2005) (117)
- Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF) (2018) (116)
- Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. (2014) (116)
- Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). (2012) (115)
- Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group. (2014) (114)
- Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. (2012) (113)
- Angiosarcoma: state of the art and perspectives. (2011) (111)
- Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. (2014) (110)
- Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study. (2010) (110)
- Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. (2017) (109)
- Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. (2019) (107)
- Totally implantable venous access port systems and risk factors for complications: a one-year prospective study in a cancer centre. (2011) (103)
- Risk factors for wound infection in head and neck cancer surgery: A prospective study (2001) (102)
- Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. (2016) (100)
- Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO). (2016) (100)
- Surgery in reference centers improves survival of sarcoma patients: a nationwide study (2019) (96)
- Improved survival using specialized multidisciplinary board in sarcoma patients. (2017) (95)
- Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. (2019) (93)
- Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. (2012) (93)
- Solitary Fibrous Tumors and So-Called Hemangiopericytoma (2012) (92)
- Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)† (2015) (90)
- Adult desmoid tumors: biology, management and ongoing trials (2017) (88)
- Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. (2015) (88)
- Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship? (2011) (88)
- Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). (2011) (85)
- Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. (2015) (85)
- Sorafenib in patients with progressive epithelioid hemangioendothelioma (2013) (84)
- Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. (2019) (84)
- Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database (2017) (84)
- Primary Mucosal Melanoma of Head and Neck: Prognostic Value of Clear Margins (2006) (83)
- Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. (2015) (82)
- Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. (2011) (81)
- Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. (2014) (78)
- Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. (2018) (77)
- Frequency of Certain Established Risk Factors in Soft Tissue Sarcomas in Adults: A Prospective Descriptive Study of 658 Cases (2008) (76)
- Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network (2020) (76)
- Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program (2013) (73)
- Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. (2012) (68)
- GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. (2013) (64)
- Risk factors for early catheter‐related infections in cancer patients (2007) (62)
- Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm-a position paper from the Italian and the French Sarcoma Group. (2014) (62)
- Radiotherapy alone for Merkel cell carcinoma: a comparative and retrospective study of 25 patients. (2011) (61)
- Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft‐tissue sarcoma patients in the competing risks setting (2014) (61)
- Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group. (2015) (60)
- A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. (2015) (59)
- Additional direct medical costs associated with nosocomial infections after head and neck cancer surgery: a hospital-perspective analysis. (2008) (59)
- Surgery in reference centers improves survival of sarcoma patients: a nationwide study. (2019) (58)
- Pronostic factors of synchronous brain metastases from lung cancer. (2001) (56)
- Head and neck soft tissue sarcomas of adult: prognostic value of surgery in multimodal therapeutic approach. (2004) (56)
- A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group (2013) (55)
- Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. (2019) (53)
- A Universal Formula Based on Cystatin C to Perform Individual Dosing of Carboplatin in Normal Weight, Underweight, and Obese Patients (2009) (53)
- Prognostic factors among cancer patients with good performance status screened for phase I trials (2008) (52)
- Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. (2015) (52)
- Head and neck cancer surgery in the elderly--does age influence the postoperative course? (2010) (51)
- Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics (2013) (48)
- O-Mel-Inib: A Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose Imatinib mesylate in metastatic uveal melanoma (2008) (46)
- Prognostic factors for adult sarcomas of head and neck. (2008) (46)
- Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO) (2013) (45)
- Adjuvant radiation therapy in metastatic lymph nodes from melanoma (2011) (44)
- Psychosocial factors involved in delayed consultation by patients with head and neck cancer (2005) (44)
- Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis (2010) (43)
- The free vascularized flap and the pectoralis major pedicled flap options: comparative results of reconstruction of the tongue. (2009) (43)
- Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group (2015) (42)
- Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF). (2017) (42)
- Paclitaxel/carboplatin with or without belinostat as empiric first‐line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial (2015) (40)
- Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever. (2004) (40)
- Gemcitabine-based chemotherapy in sarcomas: A systematic review of published trials. (2016) (40)
- Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors (2018) (40)
- Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma (2009) (40)
- Factors determining length of the postoperative hospital stay after major head and neck cancer surgery. (2008) (40)
- Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review (2013) (39)
- Long‐term recurrence of soft tissue sarcomas: Prognostic factors and implications for prolonged follow‐up (2014) (39)
- Oral metronomic cyclophosphamide in elderly with metastatic melanoma (2010) (39)
- REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis (2017) (39)
- Crossed views of burden and emotional distress of cancer patients and family caregivers during palliative care (2016) (39)
- Transgelin is a novel marker of smooth muscle differentiation that improves diagnostic accuracy of leiomyosarcomas: a comparative immunohistochemical reappraisal of myogenic markers in 900 soft tissue tumors (2013) (38)
- Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. (2015) (38)
- Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy. (2010) (38)
- Watch and Wait Approach for Re-excision After Unplanned Yet Macroscopically Complete Excision of Extremity and Superficial Truncal Soft Tissue Sarcoma is Safe and Does Not Affect Metastatic Risk or Amputation Rate (2019) (38)
- Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. (2012) (37)
- Angiosarcomas and Taxanes (2007) (37)
- Prognostic significance of wound infections following major head and neck cancer surgery: an open non-comparative prospective study (2004) (37)
- Imatinib as a possible cause of severe rhabdomyolysis. (2008) (37)
- Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study (2018) (36)
- Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio (2016) (36)
- Imaging of the most frequent superficial soft-tissue sarcomas (2011) (36)
- Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. (2020) (36)
- Presentation and outcome of frequent and rare sarcoma histologic subtypes: A study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers (2018) (35)
- Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. (2019) (34)
- Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study (2016) (34)
- FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression (2020) (34)
- Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort (2022) (34)
- Feasibility of sentinel lymph node biopsy in multiple unilateral synchronous breast cancer: results of a French prospective multi-institutional study (IGASSU 0502). (2009) (34)
- Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort (2020) (33)
- Management of "unfavourable" carcinoma of unknown primary site: synthesis of recent literature. (2012) (33)
- Report of Eight Recent Cases of Locally Advanced Primary Pulmonary Artery Sarcomas: Failure of Doxorubicin-Based Chemotherapy (2008) (32)
- Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway. (2018) (32)
- Imaging for Metastasis in Prostate Cancer: A Review of the Literature (2020) (32)
- Localised angiosarcomas: the identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO). (2013) (30)
- Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies (2019) (30)
- Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). (2012) (30)
- Prevention of surgical site infection after breast cancer surgery by targeted prophylaxis antibiotic in patients at high risk of surgical site infection. (2007) (30)
- Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics (2010) (30)
- irRECIST and iRECIST: the devil is in the details. (2017) (30)
- Molecular targeted therapies in advanced or metastatic chordoma patients: facts and hypotheses. (2015) (29)
- Prognosis of hypercalcemia in aerodigestive tract cancers: study of 136 recent cases. (2005) (29)
- Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care (2010) (28)
- Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs (2011) (28)
- Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis (2008) (27)
- Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial (2015) (27)
- Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. (2020) (27)
- A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma (2017) (26)
- Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. (2013) (26)
- Incidence and time trends of sarcoma (2000–2013): results from the French network of cancer registries (FRANCIM) (2019) (26)
- A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours (2013) (26)
- Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review. (2017) (26)
- Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF). (2018) (26)
- Soft tissue sarcomas or intramuscular haematomas? (2009) (26)
- What does a modified-Fibonacci dose-escalation actually correspond to? (2012) (25)
- Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P). (2017) (25)
- [Epidemiology of soft tissue sarcomas in adults]. (2001) (25)
- Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy (2012) (25)
- Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis. (2015) (24)
- Previous chemotherapy as a predictor of wound infections in nonmajor head and neck surgery: Results of a prospective study (2004) (23)
- “Classical 3 + 3 design” versus “accelerated titration designs”: analysis of 270 phase 1 trials investigating anti-cancer agents (2009) (22)
- Surgery in reference centers improves survival of sarcoma patients: a nationwide study (2019) (22)
- The off-label use of targeted therapies in sarcomas: the OUTC’S program (2014) (22)
- Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO) (2016) (21)
- High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. (2012) (21)
- Life-expectancy of patients enrolled in phase 1 clinical trials: a systematic review of published prognostic models. (2012) (21)
- Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression. (2018) (21)
- A paradigm shift in tumour response evaluation of targeted therapy: the assessment of novel drugs in exploratory clinical trials (2012) (21)
- Final results of a FNCLCC French Sarcoma Group multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS). (2009) (20)
- An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment. (2012) (20)
- A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study). (2019) (20)
- [Incidence and surgical wound infection risk factors in breast cancer surgery]. (2000) (19)
- Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression. (2020) (19)
- Complication-related removal of totally implantable venous access port systems: Does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year prospective study of 4045 patients. (2017) (19)
- Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis. (2019) (18)
- Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin (2012) (18)
- Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study. (2021) (18)
- Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: A French Sarcoma Group (FSG)/ US National Cancer Institute phase II collaborative study. (2018) (18)
- Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database. (2014) (18)
- General practitioners assessment of a structured report on medical decision making by a regional multidisciplinary cancer committee. (2007) (18)
- A simple predictive model for postoperative mortality after head and neck cancer surgery with opening of mucosa. (2007) (18)
- Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial (2014) (18)
- A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors (2013) (18)
- Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study (2020) (17)
- Improved sarcoma management in a national network of reference centers: Analysis of the NetSarc network on 13,454 patients treated between 2010 and 2014. (2016) (17)
- Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy. (2018) (17)
- Définition des volumes–cibles dans les sarcomes des tissus mous des extrémités (2001) (17)
- Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. (2022) (17)
- French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak (2020) (17)
- Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature (2021) (16)
- LMS-02: A phase II single-arm multicenter study of doxorubicin in combination with trabectedin as a first-line treatment of advanced uterine leiomyosarcoma (u-LMS) and soft tissue LMS (ST-LMS): First results in patients with u-LMS. (2013) (16)
- Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer. (2020) (16)
- Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group. (2013) (16)
- Palliative Chemotherapy Does Not Improve Survival in Metastatic Esophageal Cancer (2010) (16)
- Incidence et facteurs de risque d'infections du site opératoire en chirurgie carcinologique mammaire. (2000) (16)
- Dose-Levels and First Signs of Efficacy in Contemporary Oncology Phase 1 Clinical Trials (2011) (16)
- Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients (2010) (16)
- A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery (2021) (15)
- Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma? (2012) (15)
- Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo (PL) controlled phase II trial. (2015) (15)
- Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study. (2015) (15)
- Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial (2020) (15)
- ANGIOTAX-PLUS trial: A randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS). (2014) (15)
- [French Sarcoma Group proposals for management of sarcoma patients during COVID-19 outbreak]. (2020) (14)
- Efficacy and safety of 153Sm-EDTMP as treatment of painful bone metastasis: a large single-center study (2018) (14)
- Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma (2014) (14)
- Sarcomes des tissus mous thoraciques de l’adulte : étude rétrospective de 40 cas (2003) (14)
- Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO). (2018) (14)
- Cancer-associated hypercalcaemia in squamous-cell malignancies: a survival and prognostic factor analysis. (2011) (14)
- Results of API–AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome‐09 study (2020) (14)
- Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. (2013) (14)
- Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS). (2019) (13)
- Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients (2009) (13)
- Sarcomes en territoire irradié : actualités (2010) (13)
- Non-islet-cell tumour hypoglycaemia (NICTH): About a series of 6 cases. (2018) (13)
- PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial. (2021) (13)
- ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy (2020) (13)
- How to report toxicity associated with targeted therapies? (2016) (13)
- Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. (2018) (13)
- Pulmonary blastoma in adult: Dramatic but transient response to doxorubicin plus ifosfamide (2011) (12)
- A FNCLCC French Sarcoma Group--GETO multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS) (2008) (12)
- Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study (2019) (12)
- Updated outcome with long-term follow-up of imatinib for the treatment of progressive or recurrent aggressive fibromatosis (desmoid tumor): A FNCLCC/ French Sarcoma Group phase II trial. (2016) (12)
- Neoadjuvant MDM2 antagonist RG7112 for well-differentiated and dedifferentiated liposarcomas (WD/DD LPS): A pharmacodynamic (PD) biomarker study. (2011) (12)
- LBA59 LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study (2021) (12)
- High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSé pembrolizumab study from Unicancer. (2021) (12)
- Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma. (2010) (12)
- Pain burden in desmoid tumor patients: a survey of the French Advocacy Group SOS Desmoid. (2015) (12)
- A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. (2021) (12)
- 1619O High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study (2020) (12)
- Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study (2014) (12)
- Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial (2018) (11)
- A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome (2017) (11)
- Fréquence des génopathies et des antécédents carcinologiques chez 493 adultes atteints de sarcomes viscéraux ou des tissus mous (2003) (11)
- Sarcomes des tissus mous des extrémités. Rôle de l'imagerie dans la prise en charge initiale (2006) (11)
- Publication biases and phase II trials investigating anticancer targeted therapies (2009) (11)
- Factual understanding of randomized clinical trials: a multicenter case-control study in cancer patients (2009) (11)
- Regorafenib (RE) in liposarcomas (LIPO), leiomyosarcomas (LMS), synovial sarcomas (SYN), and other types of soft-tissue sarcomas (OTS): Results of an international, double-blind, randomized, placebo (PL) controlled phase II trial. (2016) (11)
- Fièvre et tumeur solide : valeur diagnostique de la procalcitonine et de la protéine C réactive (2001) (11)
- Proof of concept: prognostic value of the plasmatic concentration of circulating cell free DNA in desmoid tumors using ddPCR (2018) (11)
- Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≥ 24 months) overall survival results. (2012) (11)
- Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma (2013) (11)
- Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival. (2011) (11)
- When cancerophobia and denial lead to death (2009) (11)
- The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature (2019) (10)
- Pronostic des sarcomes des tissus mous en territoire irradié : étude cas-témoins (2004) (10)
- Reporting adverse events in cancer surgery randomized trials: A systematic review of published trials in oesophago-gastric and gynecological cancer patients. (2016) (10)
- Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS) (2016) (10)
- Cancer-associated hypercalcemia: validation of a bedside prognostic score (2009) (10)
- Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial (2021) (9)
- LBA68 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER (2020) (9)
- Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. (2019) (9)
- Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study. (9)
- Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years (2019) (9)
- High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: First results of the AcSé pembrolizumab study (2019) (9)
- Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial. (2018) (9)
- Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma (2016) (9)
- The nationwide cohort of 26,883 patients with sarcomas treated in NETSARC reference network between 2010 and 2015 in France: major impact of multidisciplinary board presentation prior to 1st treatment (2016) (9)
- Vinorelbine in breast cancer (2008) (9)
- Determinants of the access to remote specialised services provided by national sarcoma reference centres (2021) (9)
- Inflation in the number of eligibility criteria for industry-sponsored phase II cancer clinical trial: illustration over a 20-year period. (2012) (9)
- Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas and GIST: A French Sarcoma Group phase II trial. (2017) (9)
- DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group. (2018) (9)
- Advanced Abrikossoff tumour: A metastatic or a multifocal malignancy? (2012) (9)
- Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound. (2021) (9)
- Individual Life Expectancy Estimation Using Validated Prognostic Scores for Patients with Cancer of Unknown Primary (2010) (9)
- Imatinib for the treatment of aggressive fibromatosis (desmoid tumors) failing local treatment. A phase II trial of the French Sarcoma Group. (2006) (9)
- [Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients]. (2017) (9)
- Benefits of pembrolizumab in progressive radioactive iodine refractory thyroid cancer: Results of the AcSé Pembrolizumab Study from Unicancer. (2021) (8)
- Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. (2021) (8)
- Factors favouring palliative treatment multidisciplinary decisions for newly diagnosed visceral and soft tissue sarcomas. (2008) (8)
- Impact of Trabectedin Interruption and Subsequent Rechallenge on Progression in Patients With Advanced Soft Tissue Sarcoma: Long-term Follow-up of the T-DIS trial (2018) (8)
- Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors (2012) (8)
- Tumor Calcification: A New Response Pattern of Myxoid Liposarcoma to Trabectedin (2014) (8)
- SO-8 Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair deficient advanced solid tumors: Results from the KEYNOTE-158 study (2021) (8)
- Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival. (2011) (8)
- Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. (2021) (8)
- The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value (2015) (8)
- Weekly paclitaxel in metastatic angiosarcoma. A FNCLCC French Sarcoma Group (GSF-GETO) phase II trial (2007) (8)
- Activity endpoints reported in soft tissue sarcoma phase II trials: quality of reported endpoints and correlation with overall survival. (2013) (8)
- Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study. (2021) (8)
- Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol (2020) (8)
- Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. (2014) (8)
- Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials (2020) (7)
- Home hospitalization for palliative cancer care: factors associated with unplanned hospital admissions and death in hospital (2021) (7)
- Time interval between surgery and start of adjuvant radiotherapy in patients with soft tissue sarcoma: A retrospective analysis of 1131 cases from the French Sarcoma Group. (2016) (7)
- Improvement of the initial management of sarcomas after the dissemination of evidence-based guidelines depends on the primary sarcoma location: a population-based study (2015) (7)
- Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS). (2017) (7)
- Natural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017. (2018) (7)
- A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy (2017) (7)
- Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study (2019) (7)
- Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer. (2018) (7)
- Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial (2022) (7)
- Regorafenib use as a possible cause of intestinal perforation (2013) (7)
- A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy. (2017) (7)
- "Sufficient life expectancy": an amazing inclusion criterion in cancer phase II-III trials. (2009) (7)
- Imatinib for the treatment of aggressive fibromatosis/desmoid tumors (AF/DT) failing local treatment: updated outcome and predictive factors for progression free survival. A FNCLCC French Sarcoma Group-GETO study (2007) (7)
- A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic patients previously treated with both chemotherapy and pazopanib. (2020) (7)
- Criteria for reference centers for sarcomas: volume but also long-term multidisciplinary organisation. (2019) (6)
- Midazolam sedation in palliative medicine: retrospective study in a French center for cancer control (2020) (6)
- Sarcome de l'artère pulmonaire : un diagnostic différentiel exceptionnel de l'embolie pulmonaire (2003) (6)
- Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA) (2020) (6)
- Results of the randomized phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with translocation-related sarcoma (TRS). (2013) (6)
- [Fever and solid tumor: diagnostic value of procalcitonin and C-reactive protein]. (2001) (6)
- Proposal for size justification of expanded cohort at phase-2-recommended dose (2011) (6)
- Criteria for reference centers for sarcomas: volume but also long term multidisciplinary organisation. (2019) (6)
- Cancers et pesticides : données actuelles (2007) (6)
- Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis (2010) (6)
- Results of the prospective T-DIS randomized phase II trial comparing interruption versus continuation of trabectedin after six cycles of treatment in patients (pts) with advanced soft tissue sarcoma (ASTS). (2014) (6)
- Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC (2021) (6)
- Development of a score that predicts survival among patients with bone metastasis revealing solid tumor (2008) (6)
- MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients. (2022) (6)
- Consolidation with high-dose chemotherapy for responding patients to standard chemotherapy in advanced, metastatic soft tissue sarcoma (STS): A randomized trial from FNCLCC-French Sarcoma Group. (2016) (6)
- Existe-t-il des critères diagnostiques en faveur d'une fièvre paranéoplasique ? (2000) (6)
- PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. (2020) (6)
- Inappropriate dose of multitargeted tyrosine kinase inhibitors: the original sin (2016) (6)
- Guide sur le rôle du « Docteur Junior » en oncologie médicale (2021) (5)
- Masitinib mesylate in imatinib-resistant advanced GIST: A randomized phase II trial. (2012) (5)
- [Frequency of genetic diseases and cancer antecedents in 493 adults with visceral or soft tissue sarcomas]. (2003) (5)
- Maintenance therapy and drug holiday in sarcoma patients: systematic review (2020) (5)
- Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials (2012) (5)
- Trabectedin for advanced sarcomas failing doxorubicin: Analysis of 189 unreported patients in a compassionate use program. (2009) (5)
- GDC-0449 in patients with advanced chondrosarcomas: A French Sarcoma Group (FSG)/French and U.S. National Cancer Institutes phase II collaborative study. (2012) (5)
- Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy. (2018) (5)
- Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial. (2021) (5)
- Prostate cancer related haemophagocytic syndrome: Successful treatment with chemotherapy (2012) (5)
- [Prognosis of post-irradiation soft-tissue sarcoma: case-control study]. (2004) (5)
- Survival impact of surgical management in reference centers for retroperitoneal sarcoma: A nationwide study of FSG-GETO and NETSARC. (2018) (5)
- ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based case–control study—study protocol (2019) (5)
- Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study. (2022) (5)
- MA14.07 Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer (JVDF) (2019) (5)
- Adjuvant management of operated uterine sarcomas: A single institution experience. (2019) (5)
- The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients (2018) (5)
- Update of the T-DIS randomized phase II trial: Trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS) (2016) (5)
- Évaluation prospective du bénéfice d’une antibioprophylaxie dans la chirurgie carcinologique mammaire après chimiothérapie (2004) (5)
- Carcinome à cellules de Merkel: prise en charge actuelle. (2008) (5)
- Incidence et facteurs de risque de l’encéphalopathie à l’ifosfamide chez les patients suivis pour un sarcome (2017) (5)
- A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment (2020) (4)
- Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study (2020) (4)
- Dermatofibrosarcome : prise en charge (2018) (4)
- 1474OImproved overall and progression free survival after surgery in expert sites for sarcoma patients: A nationwide study of FSG-GETO/NETSARC (2017) (4)
- [Renal colic due to kidney metastase from larynx cancer]. (2003) (4)
- Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years. (2018) (4)
- Les infections sur site opératoire en chirurgie carcinologique cervicofaciale (1999) (4)
- [Prognosis and possibilities of treatment of inaugural metastases]. (2003) (4)
- Participation in randomised clinical trials is linked to emotion regulation strategies. (2011) (4)
- Reappraisal of eligibility criteria in cancer clinical trials (2018) (4)
- Chondrosarcoma of the femur in Mazabraud's syndrome: A first case study. (2015) (4)
- Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism (2017) (4)
- Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas (2021) (4)
- Association head and neck angiosarcoma and nevoid basal cell carcinoma syndrome (Gorlin syndrome) (2005) (4)
- Reply to B. Biswas and D. Dabkara. (2016) (4)
- The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors. (2014) (4)
- Phase II study of sorafenib mesylate (So) in patients (pts) with evolutive and advanced epithelioid hemangioendothelioma (EHE) or hemangiopericytoma/solitary fibrous tumor (SFT). (2012) (4)
- Impact of adjuvant treatments on local and metastatic relapse of soft-tissue sarcoma patients in the setting of competing risks. (2013) (4)
- Determining the Length of Posttherapeutic Follow-up for Cancer Patients Using Competing Risks Modeling (2014) (4)
- Études cliniques de phases 0, 1 et 2 en cancérologie : questions d’actualité (2010) (4)
- Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials (2010) (4)
- [Epithelioid hemangioendothelioma]. (2019) (4)
- GEFCAPI 04: A phase III trial comparing a treatment oriented by a molecular analysis with CancerTYPE ID test to cisplatin-gemcitabine in patients with carcinoma of an unknown primary (CUP). (2014) (4)
- A Canceropole Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma (2008) (4)
- Brain Metastasis and Renal Cell Carcinoma: Prognostic Scores Assessment in the Era of Targeted Therapies (2019) (4)
- A stratified phase II trial investigating sorafenib (SORA) in patients (pts) with metastatic or locally advanced angiosarcoma (AS). (2010) (4)
- Is the survival of patients treated with ipilimumab affected by antibiotics? An analysis of 1585 patients from the French National hospital discharge summary database (PMSI) (2020) (4)
- Sarcomes des tissus mous des extrémités : rôle de l'imagerie dans le suivi post-thérapeutique (2006) (4)
- Abstract P3-09-06: Bintrafusp alfa (M7824), a bifunctional fusion protein targeting transforming growth factor-β and programmed death ligand 1, in advanced triple-negative breast cancer: Preliminary results from a phase 1 cohort (2020) (4)
- Phase I experience with rogaratinib in patients (pts) with urothelial carcinoma (UC) selected based on FGFR mRNA overexpression. (2020) (4)
- Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER (2019) (3)
- First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control (2016) (3)
- Overall and net survival of patients with sarcoma between 2005 and 2010: Results from the French Network of Cancer Registries (FRANCIM) (2022) (3)
- Trabectedin is an effective second-line treatment in soft tissue sarcoma patients. (2016) (3)
- Crise de colique néphrétique par migration d'un fragment de métastase rénale de carcinome épidermoïde laryngé (2003) (3)
- [Soft tissue sarcoma: role of imaging for initial diagnosis and treatment]. (2006) (3)
- A large retrospective analysis of trabectedin in 885 patients with advanced soft tissue sarcoma. (2013) (3)
- [Splicing variant of androgen receptors (AR-V7): New paradigms]. (2016) (3)
- 1413OZOLEDRONATE DOES NOT REDUCE THE RISK OF TREATMENT FAILURE IN OSTEOSARCOMA: RESULTS OF THE FRENCH MULTICENTRE OS2006 RANDOMISED TRIAL. (2014) (3)
- [Wound infection in head and neck cancer surgery]. (1999) (3)
- FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma (2021) (3)
- Predictive Value of Clinical Judgment of Tumour Progression in Phase II Trials (2012) (3)
- Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales). (2021) (3)
- Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient With Metastatic Undifferentiated Pleomorphic Sarcoma: Postscriptum From the T-Dis Trial. (2019) (3)
- Options thérapeutiques de prise en charge des sarcomes durant la pandémie COVID-19 : propositions du groupe sarcome français (2020) (3)
- Particularités méthodologiques des études cliniques appliquées à l’évaluation des thérapeutiques ciblées (2008) (3)
- Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study. (2021) (3)
- PEMBROSARC combination of MK3475 and metronomic cyclophosphamide (mCP) in patients (pts) with advanced sarcomas a multicentre phase II trial with 3 new combination strategies. (2018) (3)
- Major impact of COVID-19 national containment on activities in the French northern comprehensive cancer center (2021) (3)
- Vancomycin flush as antibiotic prophylaxis for early catheter-related infections: a cost-effectiveness analysis (2009) (3)
- Retours sur quelques importantes avancées en oncologie et hématologie de 2018 : une sélection du comité de rédaction du Bulletin du Cancer (2019) (3)
- First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices. (2017) (3)
- [Methodological approaches of clinical studies with targeted therapies]. (2008) (3)
- [Merkel cell carcinoma: current diagnosis and treatment]. (2008) (3)
- Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer (2013) (3)
- Targeting angiogenesis in advanced soft tissue sarcoma: Tivozanib - hype or me-too? (2016) (3)
- Metabolic disorders associated with the use of targeted cancer therapies (2015) (3)
- Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study (2021) (3)
- Thérapie génique du mélanome : synthèse des études cliniques publiées (2003) (3)
- Évolution du cadre réglementaire de la recherche clinique (2019) (3)
- [Dermatofibrosarcoma: Management]. (2018) (3)
- Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT. (2022) (3)
- Pembrolizumab for vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study (2021) (3)
- International single-arm phase II trial of pazopanib in advanced extraskeletal myxoid chondrosarcoma: A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study. (2017) (3)
- Florilège des actualités oncologiques internationales en 2019 (2020) (2)
- [Induction chemotherapy and larynx preservation: is such practice useful?]. (2002) (2)
- [Autoimmune hypophysitis associated with new anti-cancer immunotherapies]. (2018) (2)
- High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. (2012) (2)
- [Cancers and pesticides: current data]. (2007) (2)
- [Diagnostic management of inaugurable metastases]. (2003) (2)
- Vinorelbine in breast cancer. (2008) (2)
- [Primary soft tissue sarcoma of the chest in adults: a retrospective study of 40 cases]. (2003) (2)
- [What's new in the management of meningeal solitary fibrous tumor/hemangiopericytoma?] (2020) (2)
- Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients treated in Europe. (2022) (2)
- Survival prognostic factors for lateral bucco-pharyngeal junction squamous cell carcinoma (2008) (2)
- A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy. (2016) (2)
- A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line treatment to patients with metastatic/advanced uterine (U-LMS) and soft tissue leiomyosarcoma (ST-LMS): Final results of the LMS-02 study. (2020) (2)
- [Analysis of the factors influencing the internal reporting of nosocomial infections. A review of 108 notifications]. (2003) (2)
- Management and outcomes for primary cardiac sarcomas (PCS): A retrospective study of the French Sarcoma Group (FSG). (2011) (2)
- Sarcomes de la tête et du cou (2013) (2)
- [Definitions of target volumes in soft tissue sarcomas of the extremities]. (2001) (2)
- Surrogate properties of survival endpoints in metastatic soft-tissue sarcoma: A meta-analysis. (2015) (2)
- Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue (2016) (2)
- Undifferentiated endometrial sarcomas (UES): Results of a French sarcoma group (FSG) retrospective series of 52 patients (pts). (2017) (2)
- Activity of regorafenib in patients with non-adipocytic soft tissue sarcoma (NASTS): Evaluation of heterogeneity of treatment effect on the updated analysis of pooled cohorts. (2022) (2)
- Prospective web-based collection of sarcoma cases diagnosed and treated in France: Experience of the NetSarc network of the French Sarcoma Tumor Boards. (2012) (2)
- The out-of-field dose in radiation therapy induces delayed tumorigenesis by senescence evasion (2022) (2)
- Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study. (2022) (2)
- Facteurs pronostiques et prédictifs des sarcomes des tissus mous : application concrète de la recherche translationnelle (2009) (2)
- β-caténine et tumeurs desmoïdes : le biomarqueur idéal ? (2017) (2)
- L’année 2015 à travers le regard du comité de rédaction du Bulletin du cancer (2016) (2)
- Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma (2020) (2)
- Regorafenib (R) versus placebo (P) in soft tissue sarcomas (STS): analysis of genetic prognostic and predictive factors (2016) (2)
- Desmoid tumors located in the abdomen or associated with adenomatous polyposis: French intergroup clinical practice guidelines for diagnosis, treatment, and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). (2022) (2)
- Quels résultats de l’année 2016 vont avoir un impact sur nos pratiques ? Le point de vue du Comité de rédaction du Bulletin du Cancer (2017) (2)
- Targeting angiogenesis in advanced soft tissue sarcoma: tivozanib-hype or me-too? (2017) (2)
- [Association soft tissue sarcoma and familial adenomatous polyposis: a case-report]. (2005) (2)
- 1478PDAdult Translocation-related soft tissue sarcomas (TRS): Presentation, management and outcome of 2,143 cases confirmed by expert pathologists (2017) (2)
- 603P Objective computerized cognitive assessment in men with metastatic castrate-resistant prostate cancer (mCRPC) randomly receiving darolutamide or enzalutamide in the ODENZA trial (2021) (2)
- Lessons from three phase III trials assessing neoadjuvant treatment in sarcoma patients. (2017) (2)
- Association sarcome des tissus mous et polypose adénomateuse familiale : à propos d'un cas (2005) (2)
- 1414OBENEFIT OF MAINTENANCE THERAPY WITH TRABECTEDIN (T) BEYOND THE 6 FIRST CYCLES: RESULTS OF A PROSPECTIVE RANDOMIZED PHASE II TRIAL COMPARING INTERRUPTION VS. CONTINUATION OF T IN PATIENTS (PTS) WITH ADVANCED SOFT TISSUE SARCOMA (ASTS): AN UPDATE. (2014) (2)
- [Gene therapy of melanoma: review of published clinical trials]. (2003) (2)
- Quelques éléments particuliers concernant l’épidémiologie des sarcomes (2007) (2)
- Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF. (2020) (2)
- Potential clinical activity of pembrolizumab monotherapy in ovarian sex cords, rare epithelial carcinoma, and other rare ovarian tumor histotypes: The French AcSé pembrolizumab study from Unicancer. (2022) (2)
- Imagerie des tumeurs desmoides extra-abdominales (2005) (2)
- Lack of prognostic value of CTNNB1 mutation profile in desmoid-type fibromatosis. (2022) (2)
- Dissémination métastatique ultratardive de mélanome oculaire : à propos de deux cas (2004) (2)
- Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial (2018) (2)
- Tumeurs vasculaires primitives osseuses (2012) (2)
- Growth modulation index and RECIST-based STBSG-EORTC criteria for the assessment of drug activity in advanced soft tissue sarcoma (ASTS) patients (pts). (2012) (2)
- Imatinib in Gastrointestinal Stromal Tumor: Does Treatment Duration Matter? (2009) (2)
- O-mel-sora: A national multicenter phase II trial of sorafenib in metastatic uveal melanoma. (2014) (2)
- How to emerge from the conservatism in clinical research methodology? (2017) (2)
- Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. (2022) (2)
- Statistical controversies in clinical research: should schedules of tumor size assessments be changed? (2016) (2)
- [Phases 0, 1 and 2 oncology clinical trials: current questions]. (2010) (2)
- Post-cross-over activity of regorafenib (RE) in soft tissue sarcoma: Analysis from the REGOSARC trial. (2017) (2)
- [A prospective evaluation of antibiotic prophylaxis efficacy for breast cancer surgery following previous chemotherapy]. (2004) (2)
- Le variant 7 du récepteur aux androgènes (« AR-V7 ») : évolution des concepts (2016) (2)
- Regorafenib for the Treatment of Sarcoma (2022) (2)
- ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC). (2021) (2)
- Sunitinib with concomitant radiation therapy in inoperable sarcomas: Final results from the dose escalation and expansion parts of a multicenter phase I study. (2022) (2)
- PRognostic factor of Early Death In phase II Trials or the end of ‘sufficient life expectancy’ as an inclusion criterion? (PREDIT model) (2016) (2)
- Prognosis value of S45F mutation of CTNNB1 in desmoid-type fibromatosis (DF): Prospective analysis of 500 consecutive patients (pts) from ALTITUDES trial. (2021) (1)
- Gestion des toxicités induites par les inhibiteurs des points de contrôle immunitaire en oncologie : cartographie des pratiques françaises (2022) (1)
- 3400 Management of Desmoid Tumours (DT): A nationwide survey after labeling of 2 expert networks (RRePS and NetSarc) (2015) (1)
- Efficacy of the Royal Marsden Score (RMS) to improve the selection patients (pts) considered for participation to dose-seeking phase I trial. (2017) (1)
- Personalised management of alveolar soft part sarcoma: a promising phase 2 study. (2019) (1)
- Discontinuation of first-line chemotherapy (CT) after 6 weeks of CT in patients (pts) with metastatic squamous-cell esophageal cancer (MSEC): A randomized phase II trial. (2016) (1)
- [Prognostic and predictive factors of soft tissue sarcoma: a daily use of translational research]. (2009) (1)
- Very low seroprevalence of sars-cov-2 among health care personnel (HCP) in a French northern comprehensive cancer center at the end of first national containment. (2021) (1)
- A phase II trial of sorafenib (SO) in advanced chordoma patients (pt). (2015) (1)
- Index de compréhension des essais cliniques randomisés en oncologie (2009) (1)
- Risk factors for ifosfamide-related encephalopathy (IRE) in sarcoma (S) patients (pts). (2015) (1)
- Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program (2013) (1)
- [Soft sarcoma tissue of extremities: medical imagery in post-therapeutic follow-up]. (2006) (1)
- Cancers de primitif inconnu : de l’autopsie à l’analyse épigénétique (2017) (1)
- Cancer de la prostate et gènes de réparation de l’ADN (2017) (1)
- Desmoid-type fibromatosis: toward a holistic management (2021) (1)
- Soft tissue sarcoma incidences and clinical characteristics are significantly different in France and Taiwan (2022) (1)
- Chimiothérapie d'induction et préservation laryngée : qu'en est-il en pratique ? (2002) (1)
- Everolimus and sunitinib as first- and second-line treatments of patients with metastatic papillary renal cell carcinoma (pRCC): A retrospective study of the GETUG (Groupe Français d’Etude des Tumeurs Uro-Génitales). (2016) (1)
- L’hypophysite auto-immune, complication des nouvelles immunothérapies anticancéreuses (2018) (1)
- [Carcinoma of unknown primary site: From necropsy to epigenetic analysis]. (2017) (1)
- A national registry for the off-label use of targeted therapies in patients (pts) with malignant mesenchymal tumors: A retrospective study from the GSF-GETO. (2010) (1)
- Dose-seeking phase I trials (DSP1T) for currently approved molecular-targeted therapies (MTT): We are still far from using appropriate designs. (2014) (1)
- Nationwide Incidence of Sarcomas and Tumors of Intermediate Malignancy in France (2020) (1)
- Increasing targeted therapy options for patients with relapsed cancer with broader somatic gene panel analysis from the primary tumor: The Profiler02 randomized phase II trial. (2022) (1)
- Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN). (2021) (1)
- Circulating vascular endothelial growth factor (VEGF) as prognostic factor of progression-free survival in patients with advanced chordoma receiving sorafenib: An analysis from a phase II trial of the French Sarcoma Group (GSF/GETO) (2016) (1)
- The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer (2022) (1)
- [Are there criteria for the diagnosis of paraneoplastic fever?]. (2000) (1)
- [Clinical equipoise and randomised clinical trials in oncology]. (2009) (1)
- Efficacy of Quadramet® (QUA) as treatment of painful bone metastasis: A large single-center study (2016) (1)
- Primitive neuroectodermal tumour of the duodenum with unexpected lymph node involvement (2008) (1)
- 3435 A non-interventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma (STS): The first interim analysis of Y-IMAGE study (2015) (1)
- LBA55Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: Final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial (2017) (1)
- [Usefulness of social and educational approach in adolescents and young adults with cancer: The Lille team's experience]. (2016) (1)
- What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trials. (2014) (1)
- [Primary leiomyosarcoma of pulmonary artery: a rare tumor mis-diagnosed as pulmonary embolism]. (2003) (1)
- Intérêt d’une approche socioéducative dans l’accompagnement des adolescents et jeunes adultes atteints de cancer : l’exemple lillois (2016) (1)
- Senescence induced by UVB in keratinocytes impairs amino acids balance. (2022) (1)
- [Ultra-late metastasis of ocular melanoma: about two cases]. (2004) (1)
- Neuroendocrine carcinoma of the urinary bladder: A large analysis of the French GETUG consortium. (2018) (1)
- Evaluation de la fonction glomérulaire par le dosage de la cystatine C. Absence d'influence de l'état nutritionnel (2000) (1)
- Silent hereditary hematochromatosis as a susceptibility factor of doxorubicin-induced acute cardiac failure. (2010) (1)
- [Evolution of the regulatory framework in clinical research]. (2019) (1)
- EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT) (2019) (1)
- 2294 Growth modulation index (GMI) to assess salvage chemotherapy benefit after FOLFIRINOX progression in metastatic pancreatic adenocarcinoma (2015) (1)
- Heritable defects in telomere and mitotic function selectively predispose to sarcomas (2023) (1)
- The off-label use of targeted therapies in sarcomas: the OUTC’S program (2014) (1)
- Rare bone sarcoma: A retrospective analysis of 149 adult patients from the French Sarcoma Group. (2018) (1)
- Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer) (2022) (1)
- Selection of ultimately ill cancer patients able to fulfill a questionnaire: Identification of inherent biases. (2015) (1)
- Heritable defects in telomere and mitotic function selectively predispose to sarcomas (2023) (1)
- Quoi de neuf dans la prise en charge des tumeurs fibreuses solitaires/hémangiopéricytomes des méninges ? (2020) (1)
- Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review (2013) (1)
- SYNFRIZZ: A first-in-human (FIH) study of a radiolabeled monoclonal antibody (Mab) targeting frizzled homolog 10 (FZD10) in patients (pts) with advanced synovial sarcomas (SyS). (2017) (1)
- Traitement des sarcomes des tissus mous de l'adulte métastatiques: évolution actuelle des concepts (2010) (1)
- [Manual for "Junior Doctors" in medical oncology]. (2021) (1)
- Overview of « druggable » alterations by histological subtypes of sarcomas and connective tissue intermediate malignancies. (2020) (1)
- Is adjuvant chemotherapy useful in lobular breast cancer patients? (2011) (1)
- Équipoise clinique et études cliniques randomisées en cancérologie (2009) (1)
- Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS). (2018) (1)
- Is the maximal tolerated dose still the best primary endpoint? Analysis of 288 dose-seeking phase I trials. (2009) (1)
- Dose-response relationship in phase I clinical trials: A European Drug Development Network (EDDN) collaboration study. (2011) (1)
- Aplidine in patients with dedifferentiated liposarcomas: A French Sarcoma Group (FSG) study. (2014) (1)
- Abstract LB-190: Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas: a french sarcoma group study (2017) (1)
- Traitements systémiques des fibromatoses agressives chez l’adulte et l’enfant : niveau de preuve et questions en suspens (2020) (1)
- Cancer de primitif inconnu : les formes cliniques à expression digestive (2012) (1)
- Efficacy and safety of panobinostat (LBH-589), a histone-deacetylase inhibitor (HDACi), in patients (pts) with advanced, previously treated soft tissue sarcoma (STS) and sex cord tumors (SCT): A study from the French Sarcoma Group. (2012) (1)
- A lesion suspected of being a desmoid tumor in the context of familial adenomatous polyposis should be biopsied. (2022) (1)
- [Docetaxel and prostate cancer: Early but not too early]. (2015) (0)
- 1445PLOW SKELETAL MUSCLE DENSITY IS PREDICTIVE FOR FEBRILE NEUTROPENIA IN PATIENTS TREATED BY DOXORUBICIN/TRABECTEDIN/PEGFILGRASTIM COMBINATION AS A FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC LEIOMYOSARCOMA (LMS) (LMS02 STUDY). (2014) (0)
- 1530P Outcome of primary soft tissue or bone myoepithelial tumors (METs) (2021) (0)
- EP-1604 Feasibility of preoperative radiotherapy in localized sarcoma of the limb:a single center experience (2019) (0)
- [Prostate cancer screening: Reasons of controversy]. (2018) (0)
- [Which recent results in Oncology and Hematology will have an impact on our practices? The point of vue of Bulletin du Cancer editorial board]. (2017) (0)
- Frequency of genetic disease and previous cancer in 493 adults with visceral or soft tissue sarcomas (2003) (0)
- Cabozantinib in Advanced Ewing Sarcomas and osteosarcomas: a multicentre, single-arm, phase 2 trial (2022) (0)
- Paclitaxel once weekly (wP) combined with fixed dose of oral metronomic cyclophosphamide (OMC): A dose-escalating phase I trial. (2017) (0)
- [2019 international oncology news: A compendium]. (2020) (0)
- Why collect data on "Races/Ethnicity" in cancer clinical trials? A letter from a french investigator. (2022) (0)
- Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial (2018) (0)
- [Anti-PLD1 and anti-PD1 in advanced urothelial cancers: promises from early phase trials]. (2016) (0)
- Adult sarcomas: Incidence and initial management before implantation of regional sarcoma committee in northern France. (2010) (0)
- Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma (2016) (0)
- Inhibiteurs de tyrosine kinase comme traitement adjuvant du cancer du rein : 1 versus 3 (2017) (0)
- Prior exposure to pazopanib (PAZ) did not minor efficacy of regorafenib (REG) in non-adipocytic soft tissue sarcoma patients (pts) (2019) (0)
- [Withholding or withdrawing life-sustaining treatments in acute oncology situations: History and regulatory aspects in France]. (2021) (0)
- [Expertise for management of immune-related adverse events in cancer therapy: Mapping of French practicing]. (2022) (0)
- Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial (2018) (0)
- Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC (2023) (0)
- Low skeletal muscle density as predictive for febrile neutropenia in patients treated by doxorubicin/trabectedin/pegfilgrastim combination as a first-line treatment of advanced or metastatic leiomyosarcoma (LMS) (LMS02 study). (2014) (0)
- Pronostic factors of Synchronous Brain Metastasis (SBM) from lung cancer: a prospective study (1999) (0)
- Two cases of rare late onset life-threatening pseudoprogression with immune check point inhibitors in advanced cancer patients – a case report (2021) (0)
- [Desmoid type fibromatosis, from radical excision to molecular extirpation]. (2020) (0)
- Incidence and predictive factors of late relapse in patients with soft tissue sarcomas: Implications for prolonged follow-up. (2013) (0)
- Management and Outcomes of Adolescent and Young Adult Sarcoma Patients in the French Multicenter NETSARC Database (2020) (0)
- 673PDEVELOPMENT AND VALIDATION OF A PREDICTIVE MODEL FOR DISEASE CONTROL (DC) AT FIRST DISEASE ASSESSMENT, AMONG PATIENTS (PTS) WITH METASTATIC SQUAMOUS CELL ESOPHAGEAL CANCER (MSCC) TREATED WITH FIRST-LINE CHEMOTHERAPY (CT). (2014) (0)
- Improvement of the initial management of sarcomas after the dissemination of evidence-based guidelines depends on the primary sarcoma location: a population-based study (2015) (0)
- Abstract 45: Screening somatic genomic alteration for rare adult cancers: the SPECTA-ARCAGEN project of the EORTC/EURACAN (2022) (0)
- Treatment of Medulloblastoma in adults (2009) (0)
- [Systemic treatment for management of aggressive fibromatosis in both adult and children: Level of evidence and unsolved questions]. (2019) (0)
- Characteristics and clinical outcomes of French patients diagnosed with advanced soft tissue sarcoma (aSTS) in real-life setting: Data from the European sarcoma biological and clinical data banking (ESBCB). (2018) (0)
- [Anticancer chemotherapy, risk factor for infection at the operated site in cervicofacial surgery]. (2001) (0)
- Sorafenib in metastatic uveal melanoma : A multicentric prospective phase II study (2015) (0)
- PREDIT model: PRognostic factor of Early Death In phase II Trials or the end of ‘sufficient life expectancy’ as an inclusion criterion? (2016) (0)
- Induction chemotherapy and larynx preservation: is such attitude daily useful? (2002) (0)
- [Prostate cancer and DNA repair genes]. (2017) (0)
- Prediction of early death among patients (pts) enrolled in phase I trials: Development and validation of a new model based on platelet count and albumin level. (2012) (0)
- Long-Term Outcomes and Prognostic Factors of Patients with Metastatic Solid Tumors Admitted to the Intensive Care Unit (2022) (0)
- [Sarcomas in irradiated fields: Recent data]. (2010) (0)
- A randomized, double-blind, placebo (Pbo)-controlled phase III study of ombrabulin plus cisplatin in patients (pts) with advanced-stage soft-tissue sarcoma after failure of anthracycline and ifosfamide chemotherapies. (2013) (0)
- Improved Outcomes With Iterative Local Treatments of Oligometastases in Sarcomas: A French Sarcoma Group Study (2013) (0)
- Localized angiosarcomas (AS): Identification of prognostic factors (PF) and analysis of treatment impact—Series from the French Sarcoma Group (GSF/GETO). (2012) (0)
- Obligation de dépistage du déficit en DPD avant prescription de fluoropyrimidines (2018) (0)
- Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma (2014) (0)
- [Soft tissue sarcoma associated with chronic lymphocytic leukemia: about 5 cases]. (2005) (0)
- Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group (2021) (0)
- Early Trial Discontinuation in Toxicity-Driven, Dose-Escalating, Phase I Cancer Trials: Occurrence, Outcomes and Predictive Factors (2016) (0)
- [Cancer screening words]. (2019) (0)
- Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group (2015) (0)
- [β-catenin and desmoid tumors: The ideal biomarker?] (2017) (0)
- Tumor burden kinetics and estimation of TTP for the evaluation of response and resistance to therapy in phase II clinical trials. (2014) (0)
- P.78 Cost of wound infection (WI) in major headand neck cancer surgery (2005) (0)
- Exploratory analysis of prognostic factors for patients (pts) with advanced soft tissue sarcoma (ASTS) receiving combination chemotherapy: A joined study of the EORTC Soft Tissue and Bone Sarcoma Group and the French Sarcoma Group. (2011) (0)
- Guidelines for the definitions of time-to-event endpoints in randomized clinical trials: Results of the DATECAN Project for Sarcomas and GISTs. (2013) (0)
- P65 Adjuvant management of operated uterine sarcomas: a single institution experience (2019) (0)
- Abstract PS1-58: The role of resection of the primary tumour in patients with de novo oligometastatic breast cancer (OMBC) (2021) (0)
- 1115P Association between hospital stays with infection and overall survival in patients treated with ipilimumab, analysis of the French nationwide exhaustive hospital discharge database (PMSI) (2020) (0)
- Shortening the Time Interval for Soft Tissue Sarcoma Patient Referral to Expert Centers with mHealth: a retrospective study (Preprint) (2022) (0)
- 1485PLocalized undifferentiated endometrial sarcomas (LUES): Results of a French Sarcoma Group (FSG) retrospective series of 39 patients (pts) (2017) (0)
- Vaccination Coverage in Cancer Outpatients: An Interventional Multicenter Before-and-After Study (2021) (0)
- Masitinib in comparison to imatinib as first-line therapy of patients with advanced gastrointestinal stromal tumor (GIST): A randomized phase III trial. (2012) (0)
- [Notification of nosocomial infections in cancerology]. (2001) (0)
- 1627MO Systemic therapies in advanced epithelioid haemangioendothelioma (EHE): A retrospective international series from the World Sarcoma Network (2020) (0)
- Taxanes Versus Androgen Receptor Therapy as Second-Line Treatment for Castrate-Resistant Metastatic Prostate Cancer After First-Line Androgen Receptor Therapy. (2023) (0)
- 1244 POSTER An Open-Label, Multicenter, Single Arm QT Interval Prolongation Study of Eribulin Mesylate in Patients With Advanced Solid Tumours (2011) (0)
- Growth modulation index (GMI) as a metric of clinical benefit assessment among advanced soft tissue sarcoma (ASTS) patients receiving trabectedin as salvage therapy. (2012) (0)
- [Primary and secondary bone tumors]. (2009) (0)
- Is adjuvant chemotherapy useful in lobular breast cancer (LBC)? (2011) (0)
- Oral metronomic chemotherapy using cyclophosphamide in metastatic patients (pts) after standard treatment: Results of a randomized phase II trial. (2016) (0)
- Intracranial Solitary Fibrous Tumour Management: A French Multicentre Retrospective Study (2023) (0)
- [ASCO 2016: Confirmation of respective roles of docetaxel and cabazitaxel in prostate cancer patients]. (2016) (0)
- 1306 POSTER Accuracy of Clinical Judgment of Progressive Disease in Phase II Trials (2011) (0)
- High Prevalence of 5T4/Trophoblast Glycoprotein in Soft Tissue Sarcomas (2021) (0)
- Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA) (2020) (0)
- Multi-institutional european single-arm phase II trial of pazopanib in advanced typical solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study. (2019) (0)
- Development and validation of a prediction model for early death among cancer patients participating in phase I clinical trials of new cytotoxic agents (2008) (0)
- Improvement of initial management of sarcomas after diffusion of evidence-based guidelines, dependent on the primary location: A population-based study. (2014) (0)
- Nosocomial infections in cancer treatment center (2001) (0)
- Abstract 4522: Pathologic complete response rate across triple negative breast cancer subtypes in the IMMUcan study (2023) (0)
- From rare to well-done: importance of rare tumors in cancer therapeutic advances (2019) (0)
- 901 Reporting adverse events (AEs) in cancer surgery randomized trial: A systemic analysis of published trials in oesogastric (OG) and gynecological (GY) cancer patients (2015) (0)
- [Some important breakthroughs in oncology and hematology in 2018: A selection by the editorial board of Bulletin du Cancer]. (2019) (0)
- Improved local relapse-free and overall survival with secondary surgery after a first R1 or R2 resection in soft tissue sarcoma (STS) of the limbs or trunk wall: An analysis 10,931 patients (pts) in NETSARC. (2019) (0)
- [Adjuvant chemotherapy for upper tract urothelial cancer: Level of evidence IA]. (2018) (0)
- Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors (2022) (0)
- Factors of interindividual hematopoietic toxicity of carboplatin. (2010) (0)
- Prevention of wound infection in breast cancer surgery with a strategy based on administration of antibiotic prophylaxis in patients at high risk of wound infection occurrence (2006) (0)
- Nationwide incidence of sarcomas and tumors of intermediate malignancy in the NETSARC network with central pathology review: Correlation with published clinical research. (2020) (0)
- Incidence and time trends of sarcoma (2000–2013): results from the French network of cancer registries (FRANCIM) (2020) (0)
- Improved survival with secondary surgery in a reference center after a first R1 or R2 resection in soft tissue sarcoma (STS) of the limbs or trunk wall: An analysis 10931 patients (pts) in NETSARC (2019) (0)
- Prognostic factors for cancer patients with good performance status considered for inclusion in phase I clinical trials (2007) (0)
- Paraneoplastic Demyelinating Inflammatory Neuropathy Revealing Metastatic Seminoma: A Case Report (2022) (0)
- 1499PThe routine real-life use of trabectedin (T) in patients with advanced soft tissue sarcoma (STS) across Europe: An analysis of overall vs. per country results from Y-IMAGE study (2017) (0)
- Weekly paclitaxel (WP) +/- bevacizumab (B) in angiosarcoma (AS) patients (pts): Analysis of prognostic/predictive factors from a randomized phase 2 trial. (2017) (0)
- Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer (2022) (0)
- 209 The sum of gains and losses of genes encoding for protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment (2015) (0)
- [Tyrosine kinase inhibitor as adjuvant treatment of renal cell carcinoma: 1 versus 3]. (2017) (0)
- Overall survival (OS) and prognostic factors (PF) of patients (pts) with metastatic solid tumors admitted in intensive care unit (ICU). (2021) (0)
- Pre-therapeutic dihydropyridimidine dehydrogenase (DPD) deficiency screening: Impact on fluoropyrimidine dose reduction at the second chemotherapy cycle and on early severe toxicity. (2021) (0)
- [A 2021 inventory in oncology news]. (2021) (0)
- Eribulin in the soft tissue sarcoma therapeutic landscape: little is good, then more is better (2016) (0)
- “Impossible” patients in oncology: Two unusual cases (2018) (0)
- [The reality of disease: the testimony of Arthur and Isabelle Rimbaud]. (2001) (0)
- [Treatment of adult patients with metastatic sarcoma: current shift in concepts]. (2010) (0)
- Prognostic factors and therapeutic options for epithelioid hemangioendothelioma (EHE): A multicenter analysis of a series of fifty-seven cases. (2019) (0)
- 324 Dose-seeking phase I trials (DSPT) of approved molecularly targeted therapies (MTT): Exhaustiveness and readability of published clinical reports (2015) (0)
- 1534P Patterns of care and outcomes of NTRK-fusion positive sarcomas: A retrospective and prospective cases series (2021) (0)
- LBA-04The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results (2016) (0)
- Organisation of Sarcoma Patient Management in Reference Centers in Netsarc Network: Analysis of The Quality of Resection (2012) (0)
- Net survival of sarcomas according to anatomic, histology and genomic profiles in population-based cancer registries in France. (2018) (0)
- Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals (2020) (0)
- Switch in use of midazolam for cancer patients during the COVID-19 pandemic (2020) (0)
- Identification des facteurs pronostiques associés à la survie globale, la survie sans progression et la survie sans progression métastatique chez des patients atteints d'un sarcome en territoire irradié (2022) (0)
- Méthodes radiologiques d’évaluation de la réponse thérapeutique en cancérologie (2010) (0)
- [An index of understanding randomised clinical trials in oncology]. (2009) (0)
- [What role for the direct oral anticoagulants in oncology?] (2018) (0)
- National clinical-biological prospective cohort of incident cases of aggressive fibromatosis, AF (ALTITUDES) (2019) (0)
- 1650P Desmoid type fibromatosis in patients (2020) (0)
- Objective measure of patients' understanding of their role in a randomized trial: A multicenter case-control study. (2009) (0)
- Management of tumor tissue in cancer clinical trials: An ethical perspective. (2019) (0)
- P.202 Prognostic significance of hypercalcemia inaerodigestive tract cancers (2005) (0)
- Molecular targeted therapies (MTT) in advanced chordoma (AC) patients (pts). (2016) (0)
- Sarcomes (2020) (0)
- P.222 Facteurs prédictifs de mortalité postopératoire (MPO) après chirurgie carcinologique abdomino-pelvienne (2009) (0)
- Les mots du dépistage des cancers (2019) (0)
- Sarcomes des tissus mous : bénéfices et questionnements (2015) (0)
- Sarcoligo, impact du traitement local ablatif (chirurgie, radiothérapie, radiofréquence, etc.) des oligométastases sur la survie globale des patients atteints de sarcomes (2012) (0)
- Cancer de la prostate et docétaxel : plus tôt mais pas trop tôt (2015) (0)
- Tumefaction des parties molles : ne pas meconnaitre un sarcome (2009) (0)
- Handling missing covariates in observational studies: An illustration with the assessment of prognostic factors of survival outcomes in sarcoma in irradiated fields (SIF). (2022) (0)
- Erratum (0)
- [Tumor lysis syndrome with symptomatic hyperuricemia after a first chemotherapeutic treatment of undifferentiated carcinoma of the cavum]. (2002) (0)
- Hematomes musculaires spontanes et sarcomes des parties molles (2004) (0)
- Association of circulating VEGF-A levels with outcome in patients with vascular sarcomas receiving sorafenib (Sor): Exploratory analysis from AngioNext study. (2013) (0)
- Prognosis of desmoid tumors (DT): A prospective nationwide survey of 771 patients (pts). (2017) (0)
- Développement et validation d’un modèle pronostic pour prédire la mortalité à 90 jours des patients atteints de carcinomes de primitif inconnu (2008) (0)
- ASCO 2016 : confirmation des places respectives du docétaxel et du cabazitaxel dans le cancer la prostate (2016) (0)
- Predictors for malignant tissue (MT) in residual masses (RM) of non-seminomatous germ cell tumors (NSGCT) treated by chemotherapy (CT) before surgery. (2017) (0)
- La recherche en Cancérologie : la France face aux bouleversements géopolitiques et à son inégalité territoriale (2022) (0)
- Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue (2016) (0)
- A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome (2017) (0)
- L’année 2021 dans tous ses états : une synthèse digérée (2021) (0)
- Chimiothérapie adjuvante pour les tumeurs urothéliales du haut appareil urinaire : niveau de preuve IA (2018) (0)
- PRognostic factor of Early Death In phase II Trials or the end of ‘sufficient life expectancy’ as an inclusion criterion? (PREDIT model) (2016) (0)
- Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study (2019) (0)
- Adjuvant (A) and neoadjuvant (NeoA) chemotherapy (C) in resected synovial sarcoma (SS): A study of the French Sarcoma Group (GSF-GETO) (2008) (0)
- Anti-PDL1 et anti-PD1 pour les tumeurs urothéliales avancées : promesses des études de phase I et phase II (2016) (0)
- ASCO 2017 : le retour du blocage androgénique complet (2017) (0)
- Myositis ossificans circumscripta after surgery and radiotherapy and during sunitinib treatment: a case report (2022) (0)
- Autoévaluations de l'article : Tumeurs malignes primitives rares des os (hors ostéosarcome, sarcome d'Ewing, chondrosarcome et chordome) (2019) (0)
- Évaluation de critères de substitution à la survie globale dans les essais cliniques randomisés (ECR) portant sur les sarcomes en situation métastatique : une méta-analyse de 10 ECR (2015) (0)
- Nouvelle version des criteres recist : aspects pratiques et limites de l’imagerie morphologique (2009) (0)
- P.182 Impact pronostique des variables thérapeutiques sur une cohorte de patients avec cancers de l’œsophage cervical et de l’œsophage sus-carénaire traités par radiochimiothérapie (RCT) exclusive (2009) (0)
- Impact of the COVID-19 pandemic on clinical activity during the lockdown in North France: A single center experience. (2021) (0)
- Prospective study of concomitant stereotaxic reirradiation and mitomycin with cetuximab for recurrent head and neck cancer. (2015) (0)
- Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients (2019) (0)
- La chimiothérapie intra-artérielle (CIA) (2002) (0)
- Docetaxel (DOC) versus new androgen receptor-targeted agent (ART) in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) having received abiraterone (ABI) or enzalutamide (ENZA) as first-line (L1). (2020) (0)
- Clinical outcome and prognostic factors at baseline among patients included in a phase II trial: The SBP2 study. (2015) (0)
- Analyse de livres (2022) (0)
- Abstract 1965: Predictive and prognostic value of miRNA expression profile in aggressive fibromatosis treated with imatinib. (2013) (0)
- [Cancer research: France facing geopolitical changes and territorial inequality]. (2022) (0)
- Les sarcomes à translocation chez l’adulte : les données de la base clinico-biologique nationale des sarcomes (2017) (0)
- [Before seasonal influenza, vaccination of cancer patients and healthcare givers]. (2019) (0)
- La « Limitation et/ou arrêt des thérapeutiques » (LAT) en oncologie face à une situation aigüe : historique et aspects réglementaires en France (0)
- [Phase 1 of clinical trial: The issue of dose-escalating]. (2016) (0)
- 624P Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound (2020) (0)
- [Interest of imaging for the monitoring of a treated cancer: simplified use of likelyhood ratio. The example of soft tissue tumor]. (2006) (0)
- Emerging Role of Multikinase Inhibitors in Desmoid Tumor Management. (2019) (0)
- De la déclaration des infections nosocomiales en cancérologie (2001) (0)
- Iconographies supplémentaires de l'article : Sarcomes de la tête et du cou (2013) (0)
- REGOSTA: A randomized, placebo-controlled, double-blinded, multicenter study evaluating the efficacy and safety of regorafenib (REGO) as maintenance therapy after first-line treatment in patients (pts) with osteosarcoma (OS) and non-osteosarcomas (non-OS) of bone (non-Ewing, non-chondrosarcomas and (2021) (0)
- 5108 Sarcomes des parties molles : role de l’imagerie dans la prise en charge et le suivi (2005) (0)
- 6523 Palliative chemotherapy does not improve survival in metastatic oesophageal cancer (2009) (0)
- Survival of patients considered for participation to contemporary dose-seeking phase trial: Matter of tumour burden, nature of treatment or of dose-levels? (2017) (0)
- Management of metastatic prostate cancer patients in first line: Audit of real-life practices. (2016) (0)
- Relation entre l’albumine et l’intensité de dose de trabectedine administrée chez des patients atteints de sarcome métastatique (2016) (0)
- Dépistage du cancer de la prostate : éléments de la controverse (2018) (0)
- Iconographies supplémentaires de l'article : Hémangioendothéliome épithélioïde (2018) (0)
- Syndrome de lyse tumorale avec hyperuricémie symptomatique après une première cure de chimiothérapie pour carcinome indifférencié du cavum (2002) (0)
- 1084PPrognostic impact of the neutrophil-to-lymphocyte ratio (NLR) on overall survival in patients treated with chemoradiotherapy for head and neck cancer (2017) (0)
- Les desmoïdes de l’enfant et de l’adulte : de la chirurgie radicale vers une adaptation thérapeutique moléculaire (2020) (0)
- Early Trial Discontinuation in Toxicity-Driven, Dose-Escalating, Phase I Cancer Trials: Occurrence, Outcomes and Predictive Factors (2015) (0)
- Impact of abstention of diagnostic biopsy in sarcoma (2019) (0)
- Chapitre 23 – Sarcomes (2016) (0)
- Vaccination coverage in cancer outpatients: An interventional multicenter before/after study. (2021) (0)
- 920P Avelumab (anti-PD-L1) in patients with platinum-refractory/ineligible recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Results from a phase Ib cohort (2020) (0)
- [Soft tissue sarcomas: Questions about reported clinical benefit]. (2015) (0)
- P.220 - Traitement chirurgical des récidives pelviennes des cancers du rectum (2009) (0)
- Avant le retour de la grippe saisonnière, vacciner les patients, vacciner les soignants (2019) (0)
- À propos de lacunes osseuses hyperfixantes du pied gauche (2017) (0)
- Acknowledgement of Reviewers 2017 (2018) (0)
- Cancer patients (pts) being replaced in dose-seeking phase I trials (DSP1T): Occurrence, outcome, and risk factors. (2014) (0)
- Pharmacokinetic (PK) Interactions between Lapatinib (L) and Vinorelbine (VNR) in a Phase I Study in Locally Advanced or Metastatic Breast Cancer (LAMBC) Patients(Pts) Overexpressing HER2. GEP-01 – A Study of the FNCLCC-Group of Early Phase Trials. (2009) (0)
- 3402 Time interval (TI) between surgery and start of adjuvant radiotherapy (RT): A retrospective analysis of 1150 cases from the French Sarcoma Group (2015) (0)
- [2015 through the eyes of the Bulletin of Cancer editorial board]. (2016) (0)
- Autoévaluations de l'article : Tumeurs vasculaires primitives osseuses (2012) (0)
- Shortening the Time Interval for the Referral of Patients With Soft Tissue Sarcoma to Expert Centers Using Mobile Health: Retrospective Study (2022) (0)
- Impact d’un réseau de centre de référence pour le diagnostic et la prise en charge des patients atteints de sarcomes en France depuis 2010 (2023) (0)
- 1522MO Hormonal contraception and pregnancy and risk of progression or relapse in desmoid-type fibromatosis (DF) (2021) (0)
- Imaging-guided core needle biopsies (CNB) compared to surgical biopsies (SB) for soft tissue tumors: A cost-effectiveness analysis. (2010) (0)
- Symptomatic acute hypotension associated with high-dose dacarbazine (2020) (0)
- Brain metastasis in metastatic renal cell carcinoma: Predictive factors of occurrence and survival with or without antiangiogenic therapy. (2011) (0)
- Rego-SARC: Activity and safety of regorafenib (RE) in patients with metastatic soft-tissue sarcoma (STS) previously treated with anthracyclin-based chemotherapy—A multinational, randomized, placebo-controlled phase II trial. (2014) (0)
- Pain in desmoid-type fibromatosis: prevalence, determinants, and prognosis value. (2023) (0)
- Que retenir de l’année 2020 ? (2021) (0)
- Role of the investigator in phase 1 trials of anticancer drugs. (2012) (0)
- Autoévaluations de l'article : Sarcomes de la tête et du cou (2013) (0)
- Lessons from three phase III trials assessing neoadjuvant treatment in sarcoma patients. (2017) (0)
- Abstract 2578: High regulatory T cells infiltrate within tertiary lymphoid structure restricts response to immune checkpoint blockers in sarcomas (2022) (0)
- The letter responds to comment on: Anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study. (2022) (0)
- 1531P FOLFIRINOX relative dose intensity (RDI) and disease control in advanced pancreatic cancer patients (APC) (2020) (0)
- Sarcoligo: Impact of local ablative treatment of oligometastatic sarcomas on overall survival. (2012) (0)
- P043 - Délais de prise en charge des sarcomes au sein des centres labellisés NETSARC+ pendant l’épidémie de COVID-19 et analyse des déterminants: étude COV-PEC-SARC (2023) (0)
- Cancers métastatiques de primitifs inconnus : Une définition simple, un pronostic sombre : Cancers métastiques de primitifs inconnus (2003) (0)
- 1442PCHOI VS. RECIST ASSESSMENT OF TUMOR RESPONSE IN A RETROSPECTIVE ANALYSIS OF PATIENTS (PTS) RECEIVING TRABECTEDIN (T) FOR ADVANCED SOFT TISSUE SARCOMAS (ASTS). (2014) (0)
- ACCESS TO EARLY CLINICAL TRIALS IN OLDER PATIENTS IN FRANCE: AN ANALYSIS OF THE EGALICAN 2 STUDY (2019) (0)
- Is symptom worsening (SW) associated with RECIST response in patients (pts) with desmoid tumors (DT) (2016) (0)
- Why will there never be a randomized trial for NTRK-rearranged tumors? (2023) (0)
- Les auteurs (2020) (0)
- LBA57Results of the LMS03 phase II study evaluating gemcitabine combined with pazopanib as a 2nd-line treatment for metastatic/relapsed leiomyosarcomas (uterine or soft tissue) after failure of anthracycline-based chemotherapy: The UNICANCER SARCOME 11 study (2017) (0)
- Determinants of accrual period of time in dose escalating phase I trials. (2016) (0)
- Iconographies supplémentaires de l'article : Tumeurs vasculaires primitives osseuses (2012) (0)
- [2017 ASCO: Complete androgen blockade strikes back]. (2017) (0)
- Patients (pts) accessible to interview in palliative care unit: Analysis of inherent biases. (2011) (0)
- Intérêt des examens d’imagerie pour la surveillance d’un cancer traité : utilisation simplifiée des rapports de vraisemblance (2006) (0)
- [Feedback on the first three years of application of the reform of the third cycle in oncology]. (2022) (0)
- 1544P Soft tissue sarcoma (STS) incidences and clinical characteristics are significantly different between different geographic and ethnic populations (2021) (0)
- Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial (2015) (0)
- Ziv-aflibercept (A) combined to FOLFIRI as first line treatment for metastatic colorectal cancer (mCRC): Interim safety and efficacy results of the phase II PULSAR trial. (2017) (0)
- Effect of metastasis surgery on overall survival in patients (pts) with advanced soft tissue sarcoma (ASTS): A subanalysis of the PALSAR trials. (2012) (0)
- Chondrosarcome du fémur dans le cadre d’un syndrome de Mazabraud : à propos du premier cas (2015) (0)
- "TNM" at study entry in phase I trials. (2021) (0)
- Quelle place pour les anticoagulants oraux directs en cancérologie ? (2018) (0)
- Analysis of signaling pathway activity in desmoid-type fibromatosis (DF) to identify druggable pathways. (2020) (0)
- Circulating cell free tumor DNA detection as novel biomarkers to monitor desmoid tumors evolution. (2017) (0)
- Long-term survival (over 10 years) of inoperable/metastatic GISTs: A retrospective series of 141 patients (pts) of the french sarcoma group (FSG). (2017) (0)
- Determinants of the access to remote specialised services provided by national sarcoma reference centres (2021) (0)
- Association d'un sarcome des tissus mous et d'une leucémie lymphoïde chronique : à propos de cinq cas (2005) (0)
- Ewing sarcoma Family of Tumors in Older Patients (EFyTOP): Management and outcome of Ewing sarcoma family of tumors (EFTs) in patients older than 50 years. (2016) (0)
- [Requirement of DPD deficiency screening before prescription of fluoropyrimidines]. (2018) (0)
- Metastatic angiosarcomas (mAS): Identification of treatments that significantly improve the outcome. (2011) (0)
- Evaluation de la reponse therapeutique en cancerologie : aspects pratiques et limites de l’imagerie morphologique (2008) (0)
- Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer). (2022) (0)
- A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib (REG) in patients (pts) with nonadipocytic soft tissue sarcoma (STS) previously treated with pazopanib (PAZ). (2019) (0)
- La phase socle en oncologie : retour d’expérience sur les trois premières années d’application de la réforme du troisième cycle (2022) (0)
- Iconographies supplémentaires de l'article : Tumeurs malignes primitives rares des os (hors ostéosarcome, sarcome d'Ewing, chondrosarcome et chordome) (2019) (0)
- Quelques el ements particuliers concernant l'ep idemiologie des sarcomes (2007) (0)
- Effect of medical staff training on vaccination coverage in outpatients with cancer: An interventional multicenter before-and-after study (2023) (0)
- Oral metronomic cyclophosphamide (OMC) versus megestrol acetate (MA) among patients with advanced, refractory and progressive solid tumours: A randomized phase II study (2008) (0)
- Distribution and Outcome of NTRK-Rearranged Mesenchymal Tumors (NMT): An Ambispective Cases Series (2022) (0)
- Prise en charge des sarcomes utérins : l’expérience d’un centre de 2000 à 2015 (2016) (0)
- [What should we remember from 2020?] (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Nicolas Penel?
Nicolas Penel is affiliated with the following schools:
